Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme : a cohort study

Show simple item record

dc.contributor.author Tlali, Mpho
dc.contributor.author Scheibe, Andrew
dc.contributor.author Ruffieux, Yann
dc.contributor.author Cornell, Morna
dc.contributor.author Wettstein, Anja E.
dc.contributor.author Egger, Matthias
dc.contributor.author Davies, Mary-Ann
dc.contributor.author Maartens, Gary
dc.contributor.author Johnson, Leigh F.
dc.contributor.author Haas, Andreas
dc.date.accessioned 2023-08-15T08:31:05Z
dc.date.available 2023-08-15T08:31:05Z
dc.date.issued 2022-11
dc.description AVAILABILITY OF DATA AND MATERIALS : All data were obtained from the IeDEA-SA. Data cannot be made available online because of legal and ethical restrictions. To request data, readers may contact IeDEA-SA for consideration by filling out the online form available at https://www.iedea-sa.org/contact-us/ . en_US
dc.description.abstract BACKGROUND : The use of opioids is increasing globally, but data from low- and middle-income countries on opioid-related mental and behavioural disorders (hereafter referred to as opioid-related disorders) are scarce. This study examines the incidence of opioid-related disorders, opioid agonist use, and excess mortality among persons with opioid-related disorders in South Africa's private healthcare sector. METHODS : We analysed longitudinal data of beneficiaries (≥ 11 years) of a South African medical insurance scheme using reimbursement claims from Jan 1, 2011, to Jul 1, 2020. Beneficiaries were classified as having an opioid-related disorder if they received an opioid agonist (buprenorphine or methadone) or an ICD-10 diagnosis for harmful opioid use (F11.1), opioid dependence or withdrawal (F11.2-4), or an unspecified or other opioid-related disorder (F11.0, F11.5-9). We calculated adjusted hazard ratios (aHR) for factors associated with opioid-related disorders, estimated the cumulative incidence of opioid agonist use after receiving an ICD-10 diagnosis for opioid dependence or withdrawal, and examined excess mortality among beneficiaries with opioid-related disorders. RESULTS : Of 1,251,458 beneficiaries, 1286 (0.1%) had opioid-related disorders. Between 2011 and 2020, the incidence of opioid-related disorders increased by 12% (95% CI 9%-15%) per year. Men, young adults in their twenties, and beneficiaries with co-morbid mental health or other substance use disorders were at increased risk of opioid-related disorders. The cumulative incidence of opioid agonist use among beneficiaries who received an ICD-10 diagnosis for opioid dependence or withdrawal was 18.0% (95% CI 14.0-22.4) 3 years after diagnosis. After adjusting for age, sex, year, medical insurance coverage, and population group, opioid-related disorders were associated with an increased risk of mortality (aHR 2.28, 95% CI 1.84-2.82). Opioid-related disorders were associated with a 7.8-year shorter life expectancy. CONCLUSIONS : The incidence of people diagnosed with or treated for an opioid-related disorder in the private sector is increasing rapidly. People with opioid-related disorders are a vulnerable population with substantial psychiatric comorbidity who often die prematurely. Evidence-based management of opioid-related disorders is urgently needed to improve the health outcomes of people with opioid-related disorders. en_US
dc.description.department Family Medicine en_US
dc.description.librarian hj2023 en_US
dc.description.sponsorship The U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, an Ambizione fellowship and special project funding from the Swiss National Science Foundation. en_US
dc.description.uri http://www.elsevier.com/locate/drugpo en_US
dc.identifier.citation Tlali, M., Scheibe, A., Ruffieux, Y. et al. 2022, 'Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme : a cohort study', International Journal of Drug Policy, vol. 109, art. 103853, pp. 1-8, doi : 10.1016/j.drugpo.2022.103853. en_US
dc.identifier.issn 0955-3959
dc.identifier.other 10.1016/j.drugpo.2022.103853
dc.identifier.uri http://hdl.handle.net/2263/91923
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.rights © 2022 Elsevier B.V. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in International Journal of Drug Policy. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in International Journal of Drug Policy, vol. 109, art. 103853, pp. 1-8, doi : 10.1016/j.drugpo.2022.103853. en_US
dc.subject Opioid use disorders en_US
dc.subject Opioid agonist therapy en_US
dc.subject Opioid substitution therapy (OST) en_US
dc.subject South Africa (SA) en_US
dc.subject Private sector en_US
dc.subject Mortality en_US
dc.subject.other Health sciences articles SDG-03
dc.subject.other SDG-03: Good health and well-being
dc.title Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme : a cohort study en_US
dc.type Postprint Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record